FILSPARI's net sales grew sequentially by 13%, reflecting continued momentum post-full approval in IgAN. The previous quarter's focus on label expansion has shifted towards leveraging this broader ...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI ...

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in ...

The Food and Drug Administration (FDA) has granted full approval to Filspari ® (sparsentan) to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at ...

Travere also shared initial data showing that FILSPARI safely induced further proteinuria reduction when used with SGLT2 inhibitors or steroids, supportive of the flexibility to be used in ...

Travere Therapeutics (TVTX) presented new data further demonstrating the clinical benefit of FILSPARI in IgA nephropathy and reinforcing its potential in focal segmental glomerulosclerosis at the ...

Travere Therapeutics announces FDA accelerated approval of Filspari ᵀᴹ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to ...